title: Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model.
abstract: OBJECTIVE
  To discover the potential role of recombinant VEGF121 (rVEGF121) injection for the prevention of fetal growth restriction in a preeclampsia (PE) mouse model (Mus musculus).
  
  
  METHODS
  This is an experimental study of 30 pregnant mice that were randomly divided into three groups: normal, PE, and PE with rVEGF121 injection. The PE mouse model was created by injecting anti Qa-2 10 ng iv, which is deleterious to Qa-2 expression (homologous to HLA-G), from the first to the fourth day of gestation. PE was validated by measuring serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor(PIGF) and also by kidney histopathology. Recombinant VEGF121 was given on the ninth day until the 11th day of pregnancy; mice were terminated on the 16th day. Fetal weights were acquired with a Denver analytical balance. Serum levels of sFlt-1 and PlGF were measured using enzyme-linked immunosorbent assay (ELISA). The data were statistically analyzed via analysis of variance (ANOVA).
  
  
  RESULTS
  On average, fetal birth weight was 0.7150 g in the normal group, 0.4936 g in the PE group, and 0.6768 g in the PE with rVEGF121 injection group. ANOVA showed significant growth restriction in the PE group (P=0.006), confirming the use of anti Qa-2 as a suitable PE model. Kidney histopathology results, sFlt-1 levels, and PlGF levels also demonstrated that anti Qa-2 consistently conferred hallmarks of PE in mice. Vascular endothelial growth factor (VEGF) injection prevented fetal growth restriction; comparable fetal weights were observed between the PE model with VEGF treatment and the normal group (P=0.610) but differed from the untreated PE group (P=0.021).
  
  
  CONCLUSIONS
  Injection of rVEGF121 has the potential to prevent fetal growth restriction in a newly proposed PE mouse model.
authors.forename: Sri
authors.initials: S
authors.lastname: Sulistyowati
authors.forename: Muhammad Adrianes
authors.initials: MA
authors.lastname: Bachnas
authors.forename: Nuri Dyah
authors.initials: ND
authors.lastname: Anggraini
authors.forename: Eric Edwin
authors.initials: EE
authors.lastname: Yuliantara
authors.forename: Wisnu
authors.initials: W
authors.lastname: Prabowo
authors.forename: Nutria Widya Purna
authors.initials: NW
authors.lastname: Anggraini
authors.forename: Mochammad Besari Adi
authors.initials: MB
authors.lastname: Pramono
authors.lastname: Adityawarman
authors.forename: Erry Gumilar
authors.initials: EG
authors.lastname: Dachlan
authors.forename: Wiku
authors.initials: W
authors.lastname: Andonotopo
mesh_terms: D000818:Animals; D004334:Drug Administration Schedule; D005260:Female; D005317:Fetal Growth Retardation / Q000209:etiology / Q000517:prevention & control*; D046128:Fetal Therapies / Q000379:methods*; D006801:Humans; D007267:Injections; D051379:Mice; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A